HIPPO

Evidence for the interaction between IRAK1_HUMAN and MYD88_HUMAN

Sources

Publications

  • 10854325 (Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor.; Burns K, Clatworthy J, Martin L, Martinon F, Plumpton C, Maschera B, Lewis A, Ray K, Tschopp J, Volpe F; 2000)
  • 11976320 (Inhibition of interleukin-1beta -induced NF-kappa B activation by calcium/calmodulin-dependent protein kinase kinase occurs through Akt activation associated with interleukin-1 receptor-associated kinase phosphorylation and uncoupling of MyD88.; Chen BC, Wu WT, Ho FM, Lin WW; 2002)
  • 10383454 (IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family.; Wesche H, Gao X, Li X, Kirschning CJ, Stark GR, Cao Z; 1999)
  • 11960013 (IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase.; Li S, Strelow A, Fontana EJ, Wesche H; 2002)
  • 11544529 (Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction.; Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, Brint E, Dunne A, Gray P, Harte MT, McMurray D, Smith DE, Sims JE, Bird TA, O'Neill LA; 2001)
  • 21903422 (Mapping a dynamic innate immunity protein interaction network regulating type I interferon production.; Li S, Wang L, Berman M, Kong YY, Dorf ME; 2011)
  • 22011580 (A20-binding inhibitor of NF-κB (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein β activation and protects from inflammatory disease.; Zhou J, Wu R, High AA, Slaughter CA, Finkelstein D, Rehg JE, Redecke V, Häcker H; 2011)
  • 17920759 (Constitutive association of MyD88 to IRAK in HTLV-I-transformed T cells.; Mizobe T, Tsukada J, Higashi T, Mouri F, Matsuura A, Tanikawa R, Minami Y, Yoshida Y, Tanaka Y; 2007)
  • 12538665 (Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4.; Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J; 2003)
  • 17548806 (Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound.; Loiarro M, Capolunghi F, Fantò N, Gallo G, Campo S, Arseni B, Carsetti R, Carminati P, De Santis R, Ruggiero V, Sette C; 2007)
  • 16461741 (Bacterial lipoprotein-induced self-tolerance and cross-tolerance to LPS are associated with reduced IRAK-1 expression and MyD88-IRAK complex formation.; Li CH, Wang JH, Redmond HP; 2006)
  • 17276401 (The death domain of IRAK-1: an oligomerization domain mediating interactions with MyD88, Tollip, IRAK-1, and IRAK-4.; Neumann D, Kollewe C, Resch K, Martin MU; 2007)
  • 16951688 (Smad6 negatively regulates interleukin 1-receptor-Toll-like receptor signaling through direct interaction with the adaptor Pellino-1.; Choi KC, Lee YS, Lim S, Choi HK, Lee CH, Lee EK, Hong S, Kim IH, Kim SJ, Park SH; 2006)
  • 16024789 (A novel splice variant of interleukin-1 receptor (IL-1R)-associated kinase 1 plays a negative regulatory role in Toll/IL-1R-induced inflammatory signaling.; Rao N, Nguyen S, Ngo K, Fung-Leung WP; 2005)
  • 17567694 (Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines.; Abe T, Kaname Y, Hamamoto I, Tsuda Y, Wen X, Taguwa S, Moriishi K, Takeuchi O, Kawai T, Kanto T, Hayashi N, Akira S, Matsuura Y; 2007)
  • 21179087 (Oncogenically active MYD88 mutations in human lymphoma.; Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM; 2010)

Experimental systems

TechniquePSI-MI codeScore
anti tag coimmunoprecipitationMI:00070.5
Affinity Capture-Western0.5
affinity chromatography technologyMI:00040.5
in vivoMI:04930.1

other species

  • Mus musculus (Mouse)